First Brain Tumor Drug Approved in UK in 20 Years

After 20 years without a new option, adults and teenagers with certain brain tumors finally have access to a breakthrough treatment that could change how they fight their disease.

The National Institute for Health and Care Excellence approved vorasidenib for use on the NHS in England and Wales this month. Scotland approved the drug earlier, making it available across most of the UK.

The treatment targets a specific type of brain tumor called low-grade glioma in patients with a particular genetic mutation. It's designed for people who've had surgery but don't yet need the intense treatments that come with serious side effects.

What makes this approval special is what the drug does for patients. Clinical trials showed vorasidenib significantly extends the time people can live without their tumor growing, meaning they can delay or avoid radiotherapy and chemotherapy longer.

Those traditional treatments work, but they bring harsh consequences like fatigue, memory problems, and damage to healthy brain tissue. Every extra month without them is precious time patients can spend feeling more like themselves.

Dr. Karen Noble from Brain Tumour Research called this "a hugely significant moment" for patients who have waited decades for progress. Her organization contributed to the approval process, sharing patient stories that helped build the case for making the drug available.

The drug will be available immediately through the Cancer Drugs Fund while final assessments continue. Eligible patients include adults and children as young as 12 with specific astrocytoma or oligodendroglioma tumors that have IDH1 or IDH2 mutations.

The Ripple Effect

This approval represents more than just one new drug. It signals a shift in how brain tumor treatments are developed and approved in the UK after years of stagnation.

The success of vorasidenib shows that targeted therapies based on genetic mutations can work for brain tumors, opening doors for similar treatments in development. Researchers now have proof that innovative approaches can make it through the approval process.

Patient advocacy played a crucial role in bringing this treatment to the NHS. Brain Tumour Research and patients shared their experiences during consultations, demonstrating the real-world need for new options.

While advocates celebrate this win, they acknowledge the journey isn't over. Brain tumor research still receives far less funding than other cancers, and patients deserve more treatment options than one drug in 20 years.

For now, though, eligible patients across England, Wales, and Scotland have something they haven't had in decades: a new weapon in their fight, and more time before facing the toughest treatments.